REGULATORY
    Lilly’s Selpercatinib Clears Key Panel, in Line for September Approval
    August 2, 2021
    A key health ministry advisory panel on July 30 gave the thumbs-up to the approval of Eli Lilly Japan’s RET kinase inhibitor selpercatinib, known as Retevmo overseas, with the green-light putting it in line for…

    LATEST

    Daiichi Sankyo’s Q1 Sales Surge on Upbeat Global Brands
    August 2, 2021
    Daiichi Sankyo’s April-June sales soared 11.4% over a year ago on the back of strong performances from global products Lixiana (edoxaban) and Enhertu (trastuzumab deruxtecan), with the iron deficiency treatment Injectafer (ferric carboxymaltose) also lending…
    Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs
    August 2, 2021
    Astellas Pharma saw its sales grow over 6% in the first quarter of FY2021, but its profits tumbled due to impairment losses incurred from the termination of development projects, including its peanut allergy vaccine ASP0892.In…
    Takeda’s Pevonedistat Set to Be 1st Legally Backed Sakigake Drug
    August 2, 2021
    Takeda Pharmaceutical’s NEDD8-activating enzyme inhibitor pevonedistat cleared a key health ministry panel on July 30 for sakigake fast-track designation, opening the way for it to be the first drug to gain the status since the scheme earned full legal backing…

    COLUMN

    How Manufacturers Can Optimize Wholesaler Relationships and Leverage Wholesalers to Support Business Strategy
    By Eric Persoff

    Biopharmaceutical wholesalers in Japan play broader roles than their counterparts overseas. Beyond logistics and distribution, wholesalers perform a variety of tasks related to finance, safety, and commercialization. Such functions are typically cited as justification for various fees, rebates, and allowances…

    COMMENTARY

    Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
    By Yoshinori Sagehashi

    With its first “off-year” drug price revision implemented this April, Japan has now wrapped up all the reform plans agreed upon by four state ministers in 2016 for pharmaceutical pricing. As the government has provided no further mid-term vision for…

    FY2021 Drug Maker Employment Survey

    Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players

    The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

    INTERVIEW

    From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
    By Yoshinori Sagehashi

    Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

    FY2020 Drug Pricing Reform

    Japan Panel Hammers Out FY2020 Drug Pricing Reform

    Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA